Oncolytics doses first subject in pancreatic cancer trial [Yahoo! Finance]
Oncolytics Biotech Inc. - Common Shares (ONCY)
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.oncolyticsbiotech.com
Company Research
Source: Yahoo! Finance
The trial is exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1 (GOBLET) study cohort. The GOBLET study is a phase I/II multiple indication study conducted in advanced or metastatic gastrointestinal tumors. Being managed by AIO-Studien-gGmbH, the study is exploring pelareorep-based combinations and is being conducted at 17 sites in Germany. Objective response rate (ORR) and safety are the co-primary endpoints of the cohort. The new cohort will focus on patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC), evaluating the combination of pelareorep and mFOLFIRINOX with or without atezolizumab. It is supported by the $5m Pancreatic Cancer Action Network Therapeutic Accelerator Award. Oncolytics Biotech chief medical officer Thomas Heineman said: “Initiation of dosing in the mFOLFIRINOX cohort of the GOBLET study is an important milestone for Oncolytics, and we're excited to begin evaluating another pelareorep
Show less
Read more
Impact Snapshot
Event Time:
ONCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ONCY
News
- American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations RespondPR Newswire
- American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations RespondPR Newswire
- Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program [Yahoo! Finance]Yahoo! Finance
- Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer ProgramPR Newswire
- Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer ProgramPR Newswire
ONCY
Earnings
- 5/9/24 - In-Line
ONCY
Sec Filings
- 6/27/24 - Form 6-K
- 6/24/24 - Form 6-K
- 6/20/24 - Form 6-K
- ONCY's page on the SEC website